glp-1/glp-2 dual agonist GLP-1/GIP | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Science Behind GLP 1 GIP
Description
Can a patch deliver GLP-1 medication through skin
10.1016/S0140-6736(24)02317-1 [DOI] [PMC free article] [PubMed] 2.Ghusn W, Hurtado MD (2024) Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks
(3) The Danish Civil Registration System, which holds information on the date of birth, sex, emigration/immigration, and vital status 20
Eli Lilly reported these results in mid-2025, and the retatrutide availability timeline now points toward potential FDA approval no earlier than 2027, as additional phase 3 trials continue
